Cerner, Validec partner for integration of patient-generated data

Cerner has partnered with Validic, the leading digital health platform, to enable access and connectivity to patient-generated data from clinical and fitness devices and applications.

Using Validic's digital health platform, Cerner will be able to integrate clinical, fitness, wellness and nutritional data into the patient's personal health portal, HealtheLife, according to a release. With the patient's consent, that information will be sent to their EMR, giving nurses and physicians visibility to their health on a daily basis.

Cerner cited the need to provide actionable data on a regular basis, not just the information collected at the doctor's office. "Given Validic is device- and platform-agnostic, our alignment provides a much broader reach to clinical and wellness data to help propel our digital health strategy to healthcare organizations we serve, including the acceleration of remote patient monitoring, telehealth, and wellness initiatives," said Brian Carter, senior director and general manager, personal health, Cerner.

Validic provides solutions for a broad range of healthcare segments, including health systems and providers, pharmaceutical groups, research organizations and employer groups. 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.